Option chain shows key data for Ikena Oncology's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Ikena Oncology.

Ikena Oncology (NASDAQ:IKNA) Stock, Option Chain

Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

IKNA

Analyst Color

Biotech

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It &#39;Disappointing&#39;

Intraday Update

Markets

ASTI

ASTS

AWIN

BNAI

BNZI

CAVA

CHWY

CNEY

CRKN

FFIE

GENE

GYRE

HLTH

IMVT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

MRVI

NEON

ONFO

OOMA

POAI

RSLS

SCPX

SMLR

SOBR

SOPH

SRDX

STSS

SYTA

TANH

TITN

TOST

VERU

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Chicago,,Il,-,July,27,,2017:,American,Airlines,Plane,On

GSBD

This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Ikena Oncology Inc

Earnings

Press Releases

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Ikena Oncology Announces Strategic Update

UPDATE – Ikena Oncology Announces Strategic Update

Ikena Oncology Reports Second Quarter 2024 Financial Results

Ikena Oncology Reports Third Quarter 2024 Financial Results

Financing

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Assertio Holdings

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Journey Medical Corporation - Common Stock

Journey Medical

Grace Therapeutics

Iterum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

Scilex Holding

SCYNEXIS

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

HC Wainwright & Co.

Wedbush

Credit Suisse

Comments

Ikena Oncology

Ikena Oncology (IKNA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga